# Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

> **NCT01348100** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 81 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iloperidone crystalline formulation
- **DRUG:** Iloperidone microparticle formulation
- **DRUG:** Oral iloperidone

## Key facts

- **NCT ID:** NCT01348100
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2014-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01348100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01348100, "Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01348100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*